{"filing":{"accession_number":"0001628280-26-061383","cik":"0000771856","ticker":"CSBR","company_name":"CHAMPIONS ONCOLOGY, INC.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"csbr-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/csbr-20260910.htm"},"events":[{"id":32718,"run_id":30080,"accession_number":"0001628280-26-061383","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Champions Oncology issued a press release on September 10, 2026 disclosing unaudited financial results for its first quarter ended July 31, 2026. The disclosure includes revenue of $15.2 million (8.8% YoY growth), oncology services margin improvement to 51%, adjusted EBITDA of $671,000, and a net loss of $426,000. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.","company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35964,"accession_number":"0001628280-26-061383","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Champions Oncology issued a press release on September 10, 2026 disclosing unaudited financial results for its first quarter ended July 31, 2026. The disclosure includes revenue of $15.2 million (8.8% YoY growth), oncology services margin improvement to 51%, adjusted EBITDA of $671,000, and a net loss of $426,000. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:48:15.381059+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35964,"accession_number":"0001628280-26-061383","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Champions Oncology issued a press release on September 10, 2026 disclosing unaudited financial results for its first quarter ended July 31, 2026. The disclosure includes revenue of $15.2 million (8.8% YoY growth), oncology services margin improvement to 51%, adjusted EBITDA of $671,000, and a net loss of $426,000. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:48:15.381059+00:00","company_name":"CHAMPIONS ONCOLOGY, INC.","ticker":"CSBR","filing_date":"2026-09-10"}]}